Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors

A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of WJ47156 Monotherapy and in Combination With Other Anti-Tumor Therapies in Patients With Advanced Malignant Solid Tumors

This study is an open-label, dose-escalation and expansion, Phase I clinical study to evaluate the safety, tolerability, PK characteristics and preliminary antitumor activity of WJ47156 monotherapy and in combination with toripalimab in patients with advanced malignant solid tumors. The study consists of two parts, including monotherapy (Part 1) and combination therapy (Part 2).

Study Overview

• Status: Recruiting
• Conditions: Advanced Malignant Solid Tumors
• Intervention / Treatment: Drug: WJ47156; Drug: JS001+Bevacizumab; Drug: JS207

• Study Type: Interventional
• Enrollment (Estimated): 93
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: NIannian Wang, Master; Phone Number: 13161547878; Email: niannian_wang@junshipharma.com

Study Locations

• China
  • Guangdong
    • Guangzhou, Guangdong, China, 510060
      • Recruiting
      • Sun Yat-sen University Cancer Center
      • Contact: Ruihua Xu, Professor; Phone Number: 13922206676; Email: xurh@sysucc.org.cn
      • Contact: Danyun Ruan, Professor; Phone Number: 13760611470; Email: ruandy1@sysucc.org.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion criteria:

1. Male or female, 18 to 75 years old (inclusive) at the time of signing the ICF;
2. Patients with histologically or cytologically confirmed advanced malignant solid tumors；
3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
4. Life expectancy ≥ 12 weeks;
5. At least one measurable lesion according to RECIST 1.1;
6. Adequate organ function ；
7. Female or male patients of childbearing potential must agree that they have no intention to become pregnant during the study and for 6 months after the last dose, and to use highly effective contraceptive methods with their partners; );
8. Voluntary participation with full informed consent by signing an written informed consent, and with good compliance.

Exclusion Criteria

1. CNS metastasis；
2. Pleural effusion, peritoneal effusion or pericardial effusion with clinical symptoms or requiring repeated treatment (e.g., puncture or drainage);
3. Unable to swallow tablets, intestinal obstruction, or other factors affecting the administration and gastrointestinal absorption of tablets
4. For the combination therapy, patients will not be enrolled in this study if they meet any of the following criteria:

（1）Imaging findings at screening showing tumor encasement of a major vessel or significant necrosis and cavity, which may lead to a hemorrhagic risk as judged by the investigator; （2）Patients with active autoimmune diseases requiring systemic treatment (e.g., corticosteroids or immunosuppressive drugs) within 2 years prior to the first dose, including but not limited to systemic systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, vasculitis, etc. However, hypothyroidism, hypoadrenalism or hypopituitarism controlled only by hormone replacement therapy, Type I diabetes mellitus not requiring systemic treatment, psoriasis or vitiligo are allowed; （3）Previously treated with anti-PD-1/L1 therapy; （4）History of interstitial lung disease or previous history of non-infectious pneumonia treated with corticosteroids, or evidence of active pneumonia on imaging at screening; （5）Gastrointestinal perforation, fistula, abdominal abscess and ulcerative disease or history of digestive system ulcerative disease within 6 months prior to the first dose (patients with stable ulcer as assessed by the investigator may be considered for enrollment); （6）Presence of serious, unhealed, or open wounds, active ulcers, or untreated fractures; （7）History of gastrointestinal bleeding within 6 months prior to enrollment, or clear tendency of gastrointestinal bleeding (including hemorrhagic risk of severe esophageal-gastric varices, locally active digestive tract ulcerative lesion, and persistent positive fecal occult blood); （8）Clinically significant hemoptysis or tumor bleeding for any reason within one month prior to the first dose; （9）History of obvious bleeding tendency or severe coagulation dysfunction; （10）Severe drug-related adverse events leading to permanent discontinuation of the drug product or bevacizumab or its analogues; （11）Use of antiplatelet therapy or anticoagulant therapy for treatment within 14 days prior to the first dose; （12）Long-term treatment with nonsteroidal anti-inflammatory drugs is permitted for brief periods of time to relieve symptoms such as fever or pain.

5. Uncontrolled hypertension (systolic blood pressure ≥ 150 mmHg and/or diastolic blood pressure > 100 mmHg) or history of hypertensive crisis or hypertensive encephalopathy; 6. Severe cardiovascular disease, including but not limited to, myocardial infarction, severe/unstable angina, congestive heart failure (New York Heart Association [NYHA] class ≥ 2), clinically significant supraventricular or ventricular arrhythmia requiring drug intervention, aortic aneurysm requiring surgical repair, any arterial thrombosis/embolism event, Grade 3 or higher (Common Terminology Criteria for Adverse Events [CTCAE] v5.0) venous thrombosis/embolism event, transient ischemic attack, cerebral vascular accident; Left ventricular ejection fraction (LVEF) < 50% by echocardiography. Corrected QT interval (QTc) > 480 ms (calculated using the Fridericia method; if QTc is abnormal, measure 3 times at an interval of 2 minutes and use the average).

7. Serious infection (CTCAE Grade > 2) within 28 days prior to the first dose, such as serious pneumonia, bacteremia, infection and complications requiring hospitalization; or active infection or unknown cause of fever (>38.5℃) requiring systemic anti-infection treatment within 2 weeks prior to the first dose (as judged by the investigator, patients with tumor-induced fever can be enrolled);

8. Presence of active tuberculosis, hepatitis B (positive for hepatitis B surface antigen [HBsAg] and HBV DNA higher than the lower limit of detection in the study site), hepatitis C (positive for HCV antibody [HCVAb] and HCV RNA higher than the lower limit of detection in the study site);

9. History of immunodeficiency, including human immunodeficiency virus (HIV) positive test, or history of known allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;

10. History of another primary malignant tumor, with the exception of malignant tumors (e.g., basal cell carcinoma of skin and squamous cell carcinoma of skin) who have received potentially curative therapy (more than 5 years) without known active disease prior to the first dose, without potential risk for recurrence ;

11. Toxicity of previous antitumor therapy has not been recovered to CTCTAE Grade ≤ 1 or to the level specified in the inclusion/exclusion criteria, with the exception of the following: related toxicities that are well controlled as judged by the investigator and do not affect the safety and compliance of the study treatment, and can be screened after confirmation by the Sponsor;

12. Prior use of the following drugs or therapies before the first dose:

1. Having received chemotherapy, immunotherapy or other anti-tumor therapy or other investigational drug within 21 days prior to the first dose, or having received oral fluorouracil, small-molecule targeted drugs or Chinese herbal products for antitumor indications within 14 days prior to the first dose;
2. Major surgery, radiation therapy (with the exception of palliative radiation to a localized bone or brain lesion, which may be completed up to 14 days prior), or any other minor surgical procedure, excluding placement of vascular access devices, within 28 days prior to the first dose; and any biopsy or other minor procedure within 7 days prior to the first dose.
3. In the combination therapy phase, patients who have received systemic treatment with corticosteroids (more than 10 mg/day prednisone or equivalent) or other immunosuppressants within 2 weeks prior to the first dose are allowed to use inhaled or topical steroids or systemic prednisone ≤10 mg/day and equivalent drug product;

4. Having received any live vaccine or attenuated live vaccine within 28 days prior to the first dose or requiring to be vaccinated with live vaccine or attenuated live vaccine during the study (only for patients in combination therapy phase);

   13. Patients who, in the opinion of the investigator, may be at increased risk of participation in the study due to other serious physical or mental diseases or abnormal laboratory examination, or may affect the compliance with treatment or interfere with the study results, and are not suitable for participation in this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: WJ47156; If needed, additional descriptive information (including which interventions are administered in each arm) to differentiate each arm from other arms in the clinical trial.	Drug: WJ47156; Monotherapy study: participate will recepit WJ47156 monotherpy with 3 dose groups; Combination therapy study: participate will recepit WJ47156 and other study drug if in the combination therapy period
Experimental: WJ47156+JS001+Bevacizumab; If needed, additional descriptive information (including which interventions are administered in each arm) to differentiate each arm from other arms in the clinical trial.	Drug: JS001+Bevacizumab; Participants in Cohort1 of combination therapy phase will receive WJ47156 plus toripalimab and bevacizumab.Toripalimab and bevacizumab are administered intravenously.; Other Names: Toripaliman injection+Bevacizumab Injection
Experimental: WJ47146+JS207; If needed, additional descriptive information (including which interventions are administered in each arm) to differentiate each arm from other arms in the clinical trial.	Drug: JS207; Participants in Cohort2 of combination therapy phase will receive WJ47156 plus JS207. JS207 is administered intravenously.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
1.DLT	Safety endpoints: incidence and severity of DLT	1 years
2、AE	Safety endpoints: incidence and severity of adverse events (AE); Abnormal changes in laboratory and other tests with clinical significance	2.5 years
3、SAE	Safety endpoints: incidence and severity of serious adverse events (SAE); Abnormal changes in laboratory and other tests with clinical significance	2.5 years
4.MTD	Maximum tolerated dose (MTD)	1 year
5.RP2D	Recommended dose for phase II trial	1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
6.ORR	Efficacy endpoints: Objective response rate (ORR) per RECIST v1.1	2 years
7.DOR	Efficacy endpoints: Duration of response (DOR) per RECIST v1.1	2 years
8.DCR	Efficacy endpoints: Disease control rate (DCR) per RECIST v1.1	2 years
9.PFS	Efficacy endpoints: Progression-free survival (PFS) per RECIST v1.1	2 years
10.OS	Efficacy endpoints: Overall survival (OS)	2.5 years
11.Peak concentration（Cmax）	The pharmacokinetic parameters of WJ47156：peak concentration (Cmax)	2 years
12.The time to receive Cmax（Tmax）	The pharmacokinetic parameters of WJ47156 ：the time to receive Cmax（Tmax）	2 years
13. Area under the plasma concentration-time curve (AUC0-t, AUC0-∞)	The pharmacokinetic parameters of WJ47156 ：area under the plasma concentration-time curve (AUC0-t, AUC0-∞)	2 years
14.Apparent volume of distribution (Vd/F)	The pharmacokinetic parameters of WJ47156 ：apparent volume of distribution (Vd/F)	2 years
15.Apparent clearance (CL/F)	The pharmacokinetic parameters of WJ47156 ：apparent clearance (CL/F)	2 years
16.Terminal half-life (t1/2)	The pharmacokinetic parameters of WJ47156 ：terminal half-life (t1/2)	2 years
17.Steady-state peak concentration(Cmax,ss)	The pharmacokinetic parameters of WJ47156 ：steady-state peak concentration(Cmax,ss) for the main PK parameters for multiple dose	2 years
18.Plasma trough concentration at steady state(Cmin,ss)	The pharmacokinetic parameters of WJ47156 ：Plasma trough concentration at steady state(Cmin,ss) for the main PK parameters for multiple dose	2 years
19.Mean plasma concentration at steady state(Cav,ss)	The pharmacokinetic parameters of WJ47156 ：mean plasma concentration at steady state for the main PK parameters for multiple dose	2 years
20.The time to receive Cmax at steady state（Tmax,ss）	The pharmacokinetic parameters of WJ47156 ：the time to receive Cmax at steady state（Tmax,ss）for the main PK parameters for multiple dose)	2 years
21.Area under the plasma concentration-time curve at steady state (AUC0-t, ss)	The pharmacokinetic parameters of WJ47156 ：area under the plasma concentration-time curve at steady state (AUC0-t, ss)for the main PK parameters for multiple dose)	2 years
22.Accumulation factor(RAC)	The pharmacokinetic parameters of WJ47156 ：accumulation factor(RAC) at steady state for the main PK parameters for multiple dose)	2 years
23.Fluctuation coefficient(FD)	The pharmacokinetic parameters of WJ47156 ：fluctuation coefficient(FD) at steady state for the main PK parameters for multiple dose)	2 years

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
QT interval	To evaluate the correlation between plasma concentration of WJ47156 and QT interval (only applicable to the dose group of 30 mg and above of WJ47156 monotherapy)	2 years
Anti-drug antibody (ADA)	To evaluate the immunogenicity of toripalimab and JS207, including the incidence and titer of anti-drug antibody (ADA), if ADA positive, the neutralizing antibody (Nab) as needed	2 years
Blood concentration	Blood concentration of toripalimab and JS207	2 years

Collaborators and Investigators

• Sponsor: Shanghai Junshi Bioscience Co., Ltd.
• Collaborators: Sponsor GmbH

Study record dates

Study Major Dates

• Study Start (Actual): October 23, 2024
• Primary Completion (Estimated): May 15, 2026
• Study Completion (Estimated): April 30, 2027

Study Registration Dates

• First Submitted: August 22, 2024
• First Submitted That Met QC Criteria: August 22, 2024
• First Posted (Actual): August 26, 2024

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: February 19, 2025
• Last Verified: October 1, 2024

More Information

Terms related to this study

• Keywords: Solid Tumors
• Additional Relevant MeSH Terms: Neoplasms; Antineoplastic Agents, Immunological; Antineoplastic Agents; Physiological Effects of Drugs; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Growth Inhibitors; Bevacizumab
• Other Study ID Numbers: JS125-001-I

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No